Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan S Fridman

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Blood|February 5, 2010
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsAlfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, et al.
Journal of Medicinal Chemistry|June 11, 2009
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma modelEddy W Yue, Brent Douty, Brian Wayland, et al.
Blood|February 16, 2010
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosisPriya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, et al.
Cancer Cell|July 18, 2006
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancerBin-Bing S Zhou, Michael Peyton, Biao He, et al.
Cancer Discovery|January 10, 2015
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responseMaria Kleppe, Minsuk Kwak, Priya Koppikar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2010
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050Jordan S Fridman, Peggy A Scherle, Robert Collins, et al.
Blood|September 8, 2012
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaShannon L Maude, Sarah K Tasian, Tiffaney Vincent, et al.
Blood|March 4, 2010
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunityXiangdong Liu, Niu Shin, Holly K Koblish, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2007
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosisWenqing Yao, Jincong Zhuo, David M Burns, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncologyEddy W Yue, Richard Sparks, Padmaja Polam, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Blood|February 5, 2010
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsAlfonso Quintás-Cardama, Kris Vaddi, Phillip Liu, et al.
Journal of Medicinal Chemistry|June 11, 2009
Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma modelEddy W Yue, Brent Douty, Brian Wayland, et al.
Blood|February 16, 2010
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosisPriya Koppikar, Omar Abdel-Wahab, Cyrus Hedvat, et al.
Cancer Cell|July 18, 2006
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancerBin-Bing S Zhou, Michael Peyton, Biao He, et al.
Cancer Discovery|January 10, 2015
JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responseMaria Kleppe, Minsuk Kwak, Priya Koppikar, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 6, 2010
Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050Jordan S Fridman, Peggy A Scherle, Robert Collins, et al.
Blood|September 8, 2012
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemiaShannon L Maude, Sarah K Tasian, Tiffaney Vincent, et al.
Blood|March 4, 2010
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunityXiangdong Liu, Niu Shin, Holly K Koblish, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2007
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosisWenqing Yao, Jincong Zhuo, David M Burns, et al.
ACS Medicinal Chemistry Letters|May 20, 2017
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncologyEddy W Yue, Richard Sparks, Padmaja Polam, et al.
Pageof 4